Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients

Inclusion Criteria

You may be eligible for this study if you:

• Are HIV-positive.
• Are at least 13 years old (need consent of parent or guardian if under 18).
• Have an HIV count of 5,000 copies/ml or more within 30 days prior to study entry.
• Have a CD4+ count of 50 cells/mm3 or more.

Exclusion Criteria

You will not be eligible for this study if you:

• Are diagnosed with hepatitis within 30 days prior to study entry.
• Have certain serious medical conditions, including an AIDS-defining clinical condition.
• Received chemotherapy or radiation therapy within 30 days of study entry.
• Have taken any nucleoside reverse transcriptase inhibitors (NRTIs) for more than 2 weeks.
• Have ever taken 3TC.
• Have ever taken any non-nucleoside reverse transcriptase inhibitors (NNRTIs).
• Have taken medications that affect your immune system within 30 days prior to study entry.
• Have received a vaccine within 30 days prior to study entry.
• Are enrolled in another anti-HIV drug study while participating in this study.
• Abuse alcohol or drugs.
• Are pregnant or breast-feeding.